Servicenavigation

Detailseite

Zurück

Projekt Druckansicht

TRR 209:  Leberkrebs - neue mechanistische und therapeutische Konzepte in einem soliden Tumormodell

Fachliche Zuordnung Medizin
Förderung Förderung von 2017 bis 2022
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 314905040
 
Erstellungsjahr 2024

Zusammenfassung der Projektergebnisse

Liver cancer (LC) represents the sixth most frequent cancer disease and third most frequent cancer related cause of death with rising incidence. It comprises Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and primary liver tumors of mixed differentiation. LC represents an ideal model of solid cancer: major, well documented cancer risk factors are relevant for LC, namely chronic viral infection (Hepatitis B/C), obesity/metabolic syndrome (Non-alcoholic steatohepatitis), toxic injury (alcohol/aflatoxin) and chronic inflammation; still, little is known in regard to the oncogenic mechanism by which the established risk factors drive LC development, how lethal tumor progression takes place in its specific microenvironment, and how to improve treatment approaches accordingly. With excellent model systems available in LC, especially innovative mouse technologies and well annotated human LC cohorts, which reflect its causes and molecular changes, we wanted to solve these questions. Built on its strong research track, complementary and cooperative research program, and linked to well established translational structures, the aim of the SFB/TR 209 was to gain relevant new mechanistic insights and interventional strategies that are expected to impact on other solid tumor diseases even beyond this clinically relevant model cancer. The SFB/TR 209 integrated and exploited this strong and exemplary model system constellation and the expertise of internationally leading LC researchers to tackle the relevant mechanistic and interventional questions in a coordinated and complementary manner. It was the worldwide largest research consortium addressing liver cancer and already in its first funding period made a significant national and international impact by its research data, translational efforts, conferences and workshops. The research efforts of the SFB/TR 209 were well linked to strong Liver Cancer translational and clinical structures at all three partner sites. Existing efficient structures addressing the promotion of junior scientists, the compatibility of family and career, and gender issues established at all three partner sites were continuously used and specifically complemented by the SFB/TR 209. The success of the consortium is exemplified by the positioning of over 10 leading academic positions out of the excellent SFB/TR 209 project leaders and many prestigious awards such as Heisenberg Professorship, Prince Mahidol Award for Medicine and German cancer awards. Throughout the first funding period, the three locations and the subprojects have grown even closer together, forming a tightly woven cooperative network. Efficiency of the many junior researchers support measures (Gerok positions, German liver cancer stipends (MDs), Junior retreats) paid off especially through the academic positioning of many young researchers and by numerous high-class publications. Seminal findings in the first funding period were the identification of novel liver cancer initiating mechanisms (Research area A), the unravelling of liver cancer promoting mechanisms (Research area B) and the identification of novel therapeutic principles that can be addressed in liver cancer (Research area C). Despite outstanding national and international scientific successes and an unreservedly positive reevaluation, the SFB/TR 209 was not funded by the DFG in a second period.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

© 2025 DFG Kontakt / Impressum / Datenschutz

Textvergrößerung und Kontrastanpassung